Here are relevant reports on : pcr-thermocycler-market
-
Cancer Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. The growth in this market is driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players. On the other hand, a low biomarker discovery-to-approval ratio and a poor regulatory and reimbursement scenario challenge the growth of the cancer profiling market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
North America Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology]-Forecast to 2030
The North America epigenetics market, valued at USD 0.84 billion in 2024, stood at USD 0.93 billion in 2025 and is projected to advance at a resilient CAGR of 13.8% from 2025 to 2030, culminating in a forecasted valuation of USD 1.78 billion by the end of the period. Growth of the North America epigenetics market is driven by a strong, well-funded life sciences ecosystem, with rising oncology and precision-medicine programs that rely on methylation and chromatin profiling.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Microbial Identification Market by Product & Service (Instrument & Software, Consumable, Service), Method (Phenotypic, Proteomic), Technology (Mass Spectrometry, PCR), Application (Diagnostic, Food Testing), End User (Hospital) & Region - Global Forecast to 2025
The global microbial identification market growth is primed to transition from $3.2 billion in 2020 to $5.7 billion by 2025, showcasing a strong CAGR of 12.2%. Growth in this market is largely driven by the rising incidence of infectious diseases and the increasing frequency of pandemics, technological advancements, increasing food safety concerns, and increasing government initiatives and funding to detect and control antimicrobial-resistant species.
- Published: October 2020
- Price: $ 4950
- TOC Available:
-
Bioburden Testing Market by Product (Consumables, Instrument (PCR, Microscope)), Test (Anerobic, Mold/Fungi, Aerobic, Spore), Application (Raw Material, Medical Devices, Sterility Testing), End User (Pharma, Biotechnology, CMO) - Global Forecast to 2023
The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Growth in this market can be attributed to factors such as the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years. The bioburden testing market is competitive in nature, with the presence of several large and small players. Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US) are some of the leading payers in the bioburden testing market.
- Published: December 2018
- Price: $ 4950
- TOC Available:
-
Rapid Microbiology Testing Market by Product (Instruments (Automated Identification System, PCR, Mass Spectrometer) Reagent, Kits), Method (Growth, Nucleic Acid, Viability), Application (Clinical Diagnosis, Industrial, Research) & Region - Global Forecast to 2029
The global rapid microbiology testing market, valued at US$4.7 billion in 2023, stood at US$5.1 billion in 2024 and is projected to advance at a resilient CAGR of 10.1% from 2023 to 2029, culminating in a forecasted valuation of US$8.3 billion by the end of the period.The increasing use of rapid microbiology testing products can be attributed to their ability to provide quick and reliable results. These products are cost-effective and can often lead to cost savings compared to traditional methods, which is a significant factor driving market growth.
- Published: April 2024
- Price: $ 4950
- TOC Available:
-
Environmental Testing Products Market by Product (Instrument, Consumable), Technology (HPLC/LC, GC, Mass Spectrometry, NMR, IR, PCR), Application (Water (PFAS), Air, Soil (Pesticide)), End User (Industrial, Govt., Residential) - Global Forecast to 2030
The global environmental testing products market, valued at US$3.41 billion in 2023, stood at US$3.80 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$5.62 billion by the end of the period. The growing public concerns about pollution control & climate change; stringent regulatory compliance; and rising advancements in environmental testing technology are expected to contribute to market growth.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Animal Genetics Market by Animal (Bovine, Porcine), Products & Services (Genetic Materials, Genetic Testing Services), Technology (PCR, NGS, rDNA, Microarray Technology), End User (Animal Farms, Veterinary Hospitals & Clinics) - Global Forecast to 2029
The global animal genetics market, valued at US$2.76 billion in 2023, stood at US$2.97 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2029, culminating in a forecasted valuation of US$4.19 billion by the end of the period. Market growth is largely driven by factors such as the increasing consumption of animal-derived protein, growing global population & rapid urbanization, growing customer awareness, increasing demand for companion animals, focus on superior breeds, and an emphasis on genetic services to prevent genetic diseases & business loss.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
COVID 19 Impact on IVD (In Vitro Diagnostics) Market by Technology (PCR, NGS, ELISA, Rapid Test, Hematology, Hemostasis, Clinical Chemistry, Microbiology Testing, Urinalysis), End-user and Region - Global Forecast to 2025
The COVID 19 Impact on IVD (In Vitro Diagnostics) Market is expected to grow from USD 61.7 billion in 2020 to USD 77.9 billion by 2025, at a CAGR of 4.8% during the forecast period. As of 2019, some of the prominent players in the in-vitro diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Biomerieux (France), and QIAGEN (Germany), among others.
- Published: May 2020
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
